RT Journal Article
SR Electronic
T1 Alterations in pathogen-specific cellular and humoral immunity associated with acute peripheral facial palsy of infectious origin
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.13.23294046
DO 10.1101/2023.08.13.23294046
A1 Mohammad, Leyla
A1 Fousse, Mathias
A1 Wenzel, Gentiana
A1 Flotats-Bastardas, Marina
A1 Faßbender, Klaus
A1 Dillmann, Ulrich
A1 Schick, Bernhard
A1 Zemlin, Michael
A1 Gärtner, Barbara C.
A1 Sester, Urban
A1 Schub, David
A1 Schmidt, Tina
A1 Sester, Martina
YR 2023
UL http://medrxiv.org/content/early/2023/08/16/2023.08.13.23294046.abstract
AB Background and Objectives Peripheral facial palsy (PFP) is a common neurologic symptom which can be triggered by pathogens or autoimmunity as well as trauma, tumors, cholesteatoma and further local conditions disturbing the peripheral section of the nerve. In general, its cause is often difficult to identify, remaining unknown in over two thirds of cases. As we have previously shown that the quantity and quality of pathogen-specific T cells change during active infections, we hypothesized that such changes also may help to identify the causative pathogen in PFPs of unknown origin.Methods Pathogen-specific T cells were quantified in blood samples of 55 patients with PFP and 23 healthy controls after stimulation with antigens from varicella-zoster virus (VZV), herpes-simplex viruses (HSV) or borrelia. T cells were further characterized by expression of the inhibitory surface molecule CTLA-4, and markers for differentiation (CD27) and proliferation (Ki67). Pathogen-specific antibody responses were analyzed using ELISA. Results were compared with conventional diagnostics.Results Patients with PFP were more often HSV-seropositive than controls (p=0.0003), whereas VZV-and borrelia-specific antibodies did not differ between groups. Although the quantity and general phenotypical characteristics of antigen-specific T cells did not differ either, expression of CTLA-4 and Ki67 was highly increased in VZV-specific T cells of 9 PFP patients, of which 5 showed typical signs of cutaneous zoster. In the remaining 4 patients, a causal relationship with VZV was possible but remained unclear by clinical standard diagnostics. A similar CTLA-4- and Ki67-expression profile was also found in a patient with acute neuroborreliosis.Discussion In conclusion, the high prevalence of HSV-seropositivity among PFP-patients may indicate an underestimation of HSV-involvement in PFP, even though HSV-specific T-cell characteristics seem insufficient to identify HSV as a causative agent. In contrast, striking alterations in VZV- and borrelia-specific T-cell phenotype and function may allow identification of VZV- and borrelia-triggered PFPs thus bearing the potential to improve specificity of the clinical diagnosis.Competing Interest StatementT.S., M.S. and D.S. are inventors of a patent on a method for the detection of antigen-specific immune cells in extrasanguinous fluids (PCT/DE2015/000569). All other authors do not have any commercial or financial conflict of interest to declare.Funding StatementThis work was supported in part by HOMFOR, an intramural grand of Saarland University medical faculty to D.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee (Arztekammer des Saarlandes, reference number 158/13) and all participants or parents of participating children gave written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsASIantibody specific indexCMVcytomegalovirusCTLA-4cytotoxic T-lymphocyte antigen-4HSVherpes-simplex virusIFNinterferonMFImedian fluorescence intensityPFPperipheral facial palsySEBStaphylococcus aureus enterotoxin BVZVvaricella-zoster virus